Cingulate Inc (CING)
$4.79
+0.2
(+4.36%)▲
Live
Performance
- $4.55$4.80$4.79
5.01%
Downside
Day's Volatility :5.21%
Upside
0.21%
- $1.80$152.40$4.79
62.42%
Downside
52 Weeks Volatility :98.82%
Upside
96.86%
Returns
| Period | Cingulate Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 17.37% | 0.0% |
6 Months | -56.83% | 0.0% |
1 Year | -96.1% | 0.0% |
3 Years | -99.57% | -23.0% |
Highlights
Market Capitalization | 13.9M |
Book Value | $3.95 |
Earnings Per Share (EPS) | -326.4 |
Wall Street Target Price | 80.33 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -225.77% |
Return On Equity TTM | -1364.73% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -9.0M |
EBITDA | -18.0M |
Diluted Eps TTM | -326.4 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -12.5 |
EPS Estimate Next Year | -7.31 |
EPS Estimate Current Quarter | -5.64 |
EPS Estimate Next Quarter | -5.4 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1577.04%
Technicals Summary
Sell
Neutral
Buy
Cingulate Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cingulate Inc | -10.35% | -56.83% | -96.1% | -99.57% | -99.57% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cingulate Inc | NA | NA | NA | -12.5 | -13.65 | -2.26 | NA | 3.95 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cingulate Inc | Buy | $13.9M | -99.57% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Cingulate Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 178.8%
Institutional Holdings
Armistice Capital, LLC
1.87%Commonwealth Equity Services Inc
0.42%Geode Capital Management, LLC
0.12%Bank of America Corp
0.09%Virtu Financial LLC
0.08%
Company Information
Organization | Cingulate Inc |
Employees | 13 |
CEO | Dr. Shane J. Schaffer Pharm.D. |
Industry | Miscellaneous |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$4.79
+4.36%
Invesco Bulletshares 2025 Hi
$4.79
+4.36%
Schwab International Dividend Equity Etf
$4.79
+4.36%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$4.79
+4.36%
Lightpath Technologies Inc
$4.79
+4.36%
Vaneck Vectors Global Alternative Energy Etf
$4.79
+4.36%
First Trust Flexible Municipal High Income Etf
$4.79
+4.36%
Drx Dly Reg Bank Bull 3x
$4.79
+4.36%
Graniteshares 2x Long Pltr Daily Etf
$4.79
+4.36%